scholarly journals 4329 Investigating the role of Klotho in neurocognitive outcomes, brain volumes, and white matter changes in pediatric brain tumor survivors

2020 ◽  
Vol 4 (s1) ◽  
pp. 98-98
Author(s):  
Caleb Simpeh Edwards ◽  
Schuyler Stoller ◽  
Sol Savchuk ◽  
Christian Rodrigo Ugaz Valencia ◽  
Liz Tong ◽  
...  

OBJECTIVES/GOALS: Klotho is a protein linked to improved cognition in aging adults. A specific KLOTHO gene variant, KL-VS, increases circulating levels of Klotho. The current study aims to identify if the KL-VS haplotype and Klotho levels are associated with improved neurocognition in pediatric brain tumor survivors. METHODS/STUDY POPULATION: We are actively accruing pediatric brain tumor patients at UCSF alongside an existing multi-institutional cohort study investigating radiation-induced vasculopathies and cognitive outcomes in this population. Normal controls are being enrolled in parallel. Each patient undergoes: 1) single nucleotide polymorphism genotyping to identify KL-VS haplotype status, 2) enzyme-linked immunosorbent assays to measure circulating Klotho, 3) neurocognitive assessments with a computer-based, validated Cogstate battery, and 4) brain volume and white matter lesion segmentation analyses using MRI sequences obtained as part of routine care. RESULTS/ANTICIPATED RESULTS: Genotyping has been performed on 99 enrolled patients. KL-VS heterozygosity was seen in 22.7% of patients. To date, KL-VS status is not associated with neurocognitive outcomes at baseline or Year 1 testing. Association between KL-VS status, circulating Klotho levels, neurocognitive outcomes, brain volume and white matter lesion segmentation analyses is ongoing. We hypothesize that elevated Klotho levels will be associated with improved neurocognition, increased brain volumes in regions of interest and decreased white matter lesion volumes. DISCUSSION/SIGNIFICANCE OF IMPACT: If circulating Klotho leads to improved neurocognition in pediatric brain tumor survivors, Klotho levels might serve as a prognostic biomarker. Furthermore, as Klotho is being investigated for therapeutic indications, it may represent an intervention to prevent cognitive deficits in these patients.

Cancer ◽  
2003 ◽  
Vol 97 (10) ◽  
pp. 2512-2519 ◽  
Author(s):  
Wilburn E. Reddick ◽  
Holly A. White ◽  
John O. Glass ◽  
Gregory C. Wheeler ◽  
Stephen J. Thompson ◽  
...  

2018 ◽  
Vol 20 (suppl_2) ◽  
pp. i159-i159
Author(s):  
Iska Moxon-Emre ◽  
Eric Bouffet ◽  
Suzanne Laughlin ◽  
Jovanka Skocic ◽  
Cynthia de Medeiros ◽  
...  

2019 ◽  
Vol 143 (3) ◽  
pp. 483-493 ◽  
Author(s):  
Ryan Wier ◽  
Holly A. Aleksonis ◽  
Matthew M. Pearson ◽  
Christopher J. Cannistraci ◽  
Adam W. Anderson ◽  
...  

2018 ◽  
Vol 20 (suppl_2) ◽  
pp. i167-i167
Author(s):  
Cassie Kline ◽  
Erin Felton ◽  
Lennox Byer ◽  
Schuyler Stoller ◽  
Joseph Torkildson ◽  
...  

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii432-iii433
Author(s):  
Muhammad Baig ◽  
Ineke Olsthoorn ◽  
Grace Yang ◽  
Wafik Zaky ◽  
Peter Stavinoha

Abstract BACKGROUND Predicting neurocognitive outcomes in pediatric brain tumor (PBT) patients is challenging. Rarity of PBT makes inclusion of detailed risk factors (e.g., treatment modality, intensity, individual complications) difficult when sample sizes are small. The Neurological Predictor Scale (NPS) summarizes complications and treatment factors associated with neurocognitive risks and has modest validation. Recently, the Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI) was developed to evaluate the impact of treatment intensity on psychosocial outcomes but has not been compared to neurocognitive outcomes. This study compared the NPS and PNORTI in terms of relationship to neurocognitive outcomes known to be at risk in PBT survivors. METHODS 88 PBT survivors’ neuropsychological outcomes were retrospectively analyzed in relation to the NPS and PNORTI. Variables of interest included IQ, working memory, and processing speed. RESULTS NPS associated with lower IQ (rs=-.476, p=.001), lower working memory (rs=-.323, p=.010), and lower processing speed (rs=-.389, p=.007) in patients diagnosed at a younger age, but only processing speed for children diagnosed after age 7 years (rs=-.262, p=.036). PNORTI was not correlated with neurocognitive variables for either group. CONCLUSION NPS has value in predicting neurocognitive outcomes, though much more in a younger age at diagnosis group compared to older patients. The PNORTI did not demonstrate predictive value for these neurocognitive domains in our sample. Given the potential clinical and research value of a summary rating of treatment burden relating to long-term outcome, future research should include relationship to psychosocial outcomes and quality of life.


2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi142-vi142
Author(s):  
Cassie Kline-Nunnally ◽  
Erin Felton ◽  
Caleb Edwards ◽  
Heather Fullerton ◽  
Joseph Torkildson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document